Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Obicetrapib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Menarini Group Announces Positive Obicetrapib Trial Data
    Menarini Group Announces Positive Obicetrapib Trial Data

    16 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/menarini-group-announces-positive-topline-data-from-pivotal-phase-3-broadway--tandem-clinical-trials-evaluating-obicetrapib-and-the-fixed-dose-combination-obicetrapib-with-ezetimibe-10-mg-302332562.html

    PR NEWSWIRE
    16 Dec 2024
    Share Share
    NewAmsterdam shares sign drug improves cardiovascular outcomes
    NewAmsterdam shares sign drug improves cardiovascular outcomes

    11 Dec 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/newamsterdam-shares-early-sign-cholesterol-drug-improves-cardiovascular-outcomes-sending

    FIERCE BIOTECH
    11 Dec 2024
    Share Share
    NewAmsterdam Pharma Announces Positive Obicetrapib Phase 3 Data
    NewAmsterdam Pharma Announces Positive Obicetrapib Phase 3 Data

    10 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/10/2994358/0/en/NewAmsterdam-Pharma-Announces-Positive-Topline-Data-from-Pivotal-Phase-3-BROADWAY-Clinical-Trial-Evaluating-Obicetrapib-in-Patients-with-Atherosclerotic-Cardiovascular-Disease-and-.html

    GLOBENEWSWIRE
    10 Dec 2024
    Share Share
    Menarini's Obicetrapib Phase 3 Trial Positive For Familial Hypercholesterolemia
    Menarini's Obicetrapib Phase 3 Trial Positive For Familial Hypercholesterolemia

    29 Jul 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/menarini-anuncia-datos-positivos-del-ensayo-clinico-fundamental-de-fase-3-brooklyn-302209004.html

    PR NEWSWIRE
    29 Jul 2024
    Share Share
    NewAmsterdam Completes Enrollment For Obicetrapib-Ezetimibe Combo TANDEM Trial
    NewAmsterdam Completes Enrollment For Obicetrapib-Ezetimibe Combo TANDEM Trial

    08 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/08/2909562/0/en/NewAmsterdam-Pharma-Completes-Enrollment-in-Pivotal-Phase-3-TANDEM-Clinical-Trial-Evaluating-Fixed-Dose-Combination-of-Obicetrapib-plus-Ezetimibe-in-Patients-with-HeFH-and-or-ASCVD.html

    GLOBENEWSWIRE
    08 Jul 2024
    Share Share
    NewAmsterdam Announces Issuance of Composition of Matter Patent for Obicetrapib
    NewAmsterdam Announces Issuance of Composition of Matter Patent for Obicetrapib

    11 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/11/2896737/0/en/NewAmsterdam-Pharma-Announces-Issuance-of-Composition-of-Matter-Patent-for-Obicetrapib-by-the-United-States-Patent-and-Trademark-Office.html

    GLOBENEWSWIRE
    11 Jun 2024
    Share Share